{"page_content": "Our business  \nmodel\nTo deliver best-in-class treatment \noptions that meet patient needs \nand ease burden on the health care \nsystem, we utilize a business model \nwith two approaches.\nFind out more about Zealand at  \nzealandpharma.com/strategyFirst, we aim to retain full ownership and control of \nproduct candidates all the way to market in selected \ngeographies. Alternatively, we may progress clinical \ndevelopment ourselves to the point at which it makes \nbusiness sense to engage in partnerships that expand \nthe opportunity and probability of success by providing \nadditional resources and investment.\nOur agile organization engages with partners across \nthe value chain, such as academic and scientific \ninstitutions, leading contract research organizations (CROs) and contract manufacturing organizations \n(CMOs), and distribution partners.\nUpon completion of the assets of Valeritas Inc we  \nacquired an established sales force and infrastructure \nto assist with our first launch. Our new sales force \nin the United States follows our aim of retaining full \ncontrol of our current and future products. \nOptimizing \nexecution across \nthe\u00a0value chain\nInternal Drug Development\nDrug Development in Strategic PartnershipsApproved \nMedicines to \nPatientsEarly and Late \nStage Drug \nDevelopmentContract Research \nOrganizations \n(CROs)Academic and \nScientific InstitutionsContract \nManufacturing \nOrganizations (CMOs)Distribution \nPartners\nPeptide Research \nPlatformOptimizing value through internal drug development and partnerships\nMaintaining full \ncontrol and value \npotential\nExpanding \nthe\u00a0innovation \nplatform5\nZealand Pharma \u221e Corporate Responsibility Report 2020Our business model", "metadata": {"source": "NASDAQ_ZEAL_2020.pdf", "page": 4, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}